Across TCGA pan-cancer cohorts, CPT1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPT1B data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CPT1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPT1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and COAD are the cancer types where CPT1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.165	0.833	<.001	12	view →
UCEC	DFS	Median	All	0.947	0.634	.035	8	view →
COAD	DFS	Median	All	0.176	0.696	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CPT1B tumor-vs-normal RNA expression · all CPT1B data types